Seventeen private health insurance companies and more than 3,200 oncologists working in almost 200 medical groups will participate in the federal government's new cancer care project, but critics argue the program may not easily lower costs or reduce unnecessary and potentially harmful care.
Vice President Joe Biden on Wednesday stressed the importance of research data-sharing and affordability in cancer treatments as goals for his Cancer Moonshot initiative. He also threatened to pull federal funding for cancer studies that fail to publicly disclose their results.
In an emotional speech, Vice President Joe Biden urged the 30,000 oncologists attending the American Society of Clinical Oncology's annual conference to work together in the search for a cure for cancer.
It's well-known that Americans pay more for healthcare and drugs than many other nations, and a recent study confirms that the trend is the same when it comes to oncology drugs.
Some health and civil-rights advocates say guidelines that recommend women postpone breast cancer screenings until they are age 50 should not apply to black women, who are more likely to die if they contract the disease.
As providers are tasked with keeping people healthy through risk-based payment contracts, they're investing in genomics and personalized medicine in order to develop new methods of targeting patients who need early intervention.
Access to genomic data on cancer has raised hopes for rapid advances, but many worry about clinicians’ ability to effectively use the information.
Dr. Robert Califf became commissioner of the FDA in February. He brings to the job more than 30 years of experience in clinical trial research at Duke University Medical Center. Califf discusses his priorities and some of the controversies that swirled around his nomination.
Johnson & Johnson subsidiary Ethicon announced a deal to acquire NeuWave Medical, a privately held company that makes surgical oncology devices.
Cancer treatment provider 21st Century Oncology will settle with the federal government to end a dispute related to its radiation therapy testing, a company spokeswoman confirmed Thursday. It's the company's second settlement in three months.
There is “considerable variability,” and one of the most significant factors affecting quality of care is whether a patient is treated by a gynecologic oncologist at a high-volume facility, according to the report from the National Academies of Sciences, Engineering, and Medicine.
McKesson announced Thursday that it had acquired two oncology companies to bolster its specialty health segment. The combined transactions were valued at $1.2 billion, and are expected to close in the first quarter of fiscal 2017, pending customary closing conditions.